Linkedin X-twitter Youtube
Launch Digital Edition

Webinars and Sponsored Roundtables — Register Now

Thursday, April 30, 2026, 11:00 AM–12:00 PM ET
Hear an expert discuss how Memorial Sloan Kettering Cancer Center (MSKCC) is utilizing
the oncoReveal® Nexus 21-gene panel to redefine turnaround time and actionable insights
in cancer care. Dr. Ewalt shares a perceptive look at the clinical need for rapid, front-line NGS sequencing, and how a unique, purpose built targeted NGS panel (Pillar Biosciences’ oncoReveal Nexus 21 gene Panel) was developed, validated and implemented clinically by Memorial Sloan Kettering Cancer Center (MSK-REACT) to complement their current comprehensive genomic profiling (CGP) approach.

Webinar presenter Mark Ewalt, MD, Associate Medical Director for Laboratory Operations for Diagnostic Molecular Pathology in the Molecular Diagnostics Service, Department of Pathology and Laboratory Medicine, MSKCC.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Pillar Biosciences.

Register Now

Thursday, May 28, 2026, 1:00–2:00 PM ET
This session is designed to improve understanding and application of recent updates to synoptic pathology reporting protocols such as the latest Reporting Template for Reporting Results of Biomarker Testing of Specimens from Patients with Carcinoma of the Breast. These changes reflect evolving clinical guidelines that directly influence diagnostic accuracy and treatment selection in breast cancer care.

Webinar presenters Thaer Khoury, MD, FCAP, Chair, Pathology and Laboratory Medicine, Roswell Park Comprehensive Cancer Cente, and Colin Murphy,  CEO of mTuitive.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Subspecialties

Interactive Product Guides

CAP TODAY

Epredia SlideMate Laser gets MedTech Breakthrough Award

August 2024—MedTech Breakthrough announced that Epredia has been selected as the winner of best new technology solution—pathology for its SlideMate Laser printer in the 8th annual MedTech Breakthrough Awards program. The SlideMate Laser is designed for clinical laboratories and provides high-resolution, 600-dpi laser printing on microscope slides, enabling laboratories to include more identifying information directly on the tab of the slides. The technology can embed up to 50 characters in a barcode on each slide and offers on-demand and batch printing options. The laser printer’s software can be directly interfaced to a laboratory information system.

Liaison Plex Yeast Blood Culture assay gets 510(k) clearance

August 2024—Diasorin announced it has received 510(k) clearance from the FDA for the company’s Liaison Plex Yeast Blood Culture assay, the second molecular multiplexing panel on the Liaison Plex. The assay, which is driven by Gram stain, detects 16 pathogens commonly associated with fungemia. The Liaison Plex sample-to-answer system uses room-temperature consumables, has a hands-on time of two minutes, and produces results in less than two hours.

Adaptimmune gets FDA accelerated approval for Tecelra

Aug. 5, 2024—Adaptimmune Therapeutics announced FDA accelerated approval for Tecelra (afamitresgene autoleucel) for the treatment of adults with unresectable or metastatic synovial sarcoma who have received prior chemotherapy, are HLA-A*02:01P, -A*02:02P, -A*02:03P, or -A*02:06P positive, and whose tumor expresses the MAGE-A4 antigen as determined by FDA-approved or -cleared companion diagnostic devices.

 

Digging into the interpretation of TSH results

Charna Albert May 2024—In a time of wellness testing and high rates of levothyroxine prescribing for hypothyroidism, it may also be time to rethink TSH test result interpretation. Laboratory testing is more accessible now than it used to be and patients are more involved in their own care. “You’re trying to give the patient access and ability to take care of their own health. But the double-edged sword is you can start over-ordering things, and the way we’ve designed lab

PrestoCHILL for Standardized, High-Quality Frozen Sections

SEE IT IN ACTION: NSH BOOTH #515. PrestoCHILL combines a patented “face-down” embedding technique with a programmable -40°C cooling chamber to rapidly process quality frozen sections of any tissue type. With PrestoCHILL, it is finally possible to create standardized high quality frozen slides. LEARN MORE.

Labs juggle string of LDT unknowns

July 2024—Like a long-awaited second act, the FDA’s final rule regulating laboratory-developed tests as medical devices took the stage this spring. As with any FDA performance, this one opened to mixed reviews.

The spring curtain-raising followed the earlier proposed rule from last October, which drew some 6,500 responses during the public comment period. If that was an out-of-town tryout, no one quite knew what to expect from the rewrite, or if there would even be one.

As it turns out, there were indeed changes, but they didn’t necessarily bring clarity. As Jane Pine Wood, counsel for McDonald Hopkins, puts it, the final rule “certainly raised a whole lot more questions than it answered.”

The rule calls for a four-year, five-stage phaseout policy with the FDA enacting greater oversight of in vitro diagnostic products that are offered as LDTs.

Stage one, beginning on May 6, 2025, calls for labs to comply with medical device reporting requirements, correction and removal reporting requirements, and quality system requirements regarding complaint files.

HPV test self-collection set in motion

July 2024—With the Food and Drug Administration approval in May of two HPV self-collection devices for use in clinic settings, physicians in and out of the laboratory are optimistic the approach can reach underscreened patients, even if FDA approval is only a first step.

MARKETPLACE

TRENDING